Assessing Nevro: Insights From 9 Financial Analysts
Portfolio Pulse from Benzinga Insights
Nevro Corp (NYSE:NVRO) has been evaluated by 9 financial analysts over the past three months, showing a predominantly indifferent stance with 8 indifferent ratings, and 1 somewhat bearish. The 12-month price targets have seen a decrease, with an average target now at $14.89, down from $18.00, indicating a 17.28% decrease. Analysts from firms including Canaccord Genuity, Wells Fargo, and Piper Sandler have lowered their price targets, reflecting concerns over Nevro's market performance and financial health. Despite positive revenue growth of 2.05% as of December 31, 2023, Nevro's market capitalization and debt management pose challenges, with a high debt-to-equity ratio of 0.74.
May 08, 2024 | 9:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Nevro has received predominantly indifferent ratings from analysts, with a downward revision in price targets, indicating concerns over its financial health and market performance.
The collective lowering of price targets by analysts from reputable firms reflects a cautious or bearish outlook on Nevro's stock, likely due to its financial challenges such as high debt-to-equity ratio and underperformance in market capitalization. The decrease in the average price target, along with the company's recent revenue growth failing to meet industry averages, suggests potential short-term downward pressure on the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100